Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 4/20 | 0.39 |
| ▸ | MPL | P40238 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440610 | 1.00 | CRHR1 (0.41) | CRHR1OGAMPLDYRK1AMLLT1 | |
| SCHEMBL19448224 | 0.97 | OGA (0.39) | CRHR1OGAMPLDYRK1APTGDR2 | |
| SCHEMBL21005961 | 0.91 | OGA (0.40) | OGADYRK1AACHE | |
| SCHEMBL21006718 | 0.91 | OGA (0.40) | OGAMPLDYRK1AACHE | |
| SCHEMBL17386797 | 0.91 | OGA (0.40) | OGAMPLDYRK1AACHE | |
| SCHEMBL18724037 | 0.91 | OGA (0.40) | OGADYRK1AACHE | |
| SCHEMBL19448217 | 0.91 | CRHR1 (0.44) | CRHR1OGAMPLDYRK1APTGDR2 | |
| SCHEMBL18724392 | 0.90 | OGA (0.39) | OGAMPLDYRK1ARORB | |
| SCHEMBL21006189 | 0.90 | OGA (0.39) | OGAMPLDYRK1ARORB | |
| SCHEMBL17412696 | 0.89 | TRPV4 (0.43) | CRHR1OGAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845490-B | 2-acylaminothiazole derivative or salt thereof | 旭飞药业股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| CN-110845490-A | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2020-02-28 | — | — | CN | disclosed |
| CN-106414438-B | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9844549-B2 | 2-aminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-9844549-B2 | 2-aminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170290824-A1 | 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170290824-A1 | 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | CRHR1 3769/4885OGA 2832/4885MPL 3292/4885 |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | CRHR1 3937/4885OGA 2438/4885MPL 3647/4885 |
| US-20170290824-A1 | 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | CRHR1 4160/4885OGA 2653/4885MPL 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.